title: The relevance of pathological verification in suspected pancreatic cancer.
abstract: OBJECTIVE
  This population-based study assessed which factors were associated with pathological verification of pancreatic cancer.
  
  
  METHODS
  All patients diagnosed with a malignancy of the pancreas between 1993 and 2010 in the South of the Netherlands (N=3321) were included.
  
  
  RESULTS
  Pancreatic cancer was pathologically verified in 59% of patients. The proportion of verification increased over time from 56% in 1993-1996 to 69% in 2009-2010 (p<0.0001). High rates of verification were found among young patients (<50 years vs. 60-69 yrs: adjusted odds ratio (ORadj) 3.2 (95% CI: 1.9-5.4)), patients with a high socioeconomic status (high vs. low: ORadj 1.3 (95% CI: 1.1-1.7)), patients with metastatic disease (metastatic vs locoregional: ORadj 3.2 (95% CI: 2.7-3.8)) and patients treated with chemotherapy (yes vs. no: ORadj 2.4 (95% CI: 1.8-3.2)). The most favorable prognosis was found in patients with verified locoregional disease (median overall survival (mOS) 7.6 months, 95% CI: 7.1-8.6). Patients with unverified metastatic disease carried the worst prognosis (mOS 1.7 months, 95% CI: 1.4-2.0).
  
  
  CONCLUSIONS
  Verification by pathology remains preferable and desirable whenever possible. However, the median survival rate exhibited by patients without verification suggests that the vast majority of patients suffered from true invasive pancreatic cancer. This may justify treatment decisions even in the absence of pathologic verification in selected patients.
authors: The Netherlands Cancer Registry, Comprehensive Cancer Centre the Netherlands, Eindhoven, The Netherlands; Department of Oncology, Catharina Hospital, Eindhoven, The Netherlands. Electronic address: n.bernards@iknl.nl.
authors: Nienke
authors: N
authors: Bernards
authors: Department of Oncology, Catharina Hospital, Eindhoven, The Netherlands.
authors: Geert-Jan M
authors: GJ
authors: Creemers
authors: Department of Pathology, Laboratory for Pathology and Medical Microbiology (PAMM), Eindhoven, The Netherlands.
authors: Clément J
authors: CJ
authors: Huysentruyt
authors: Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands.
authors: Ignace H J T
authors: IH
authors: de Hingh
authors: Department of Surgery, Amphia Hospital, Breda, The Netherlands.
authors: George P
authors: GP
authors: van der Schelling
authors: Department of Pathology, Viecuri Medical Centre, Venlo, The Netherlands; Department of Pathology, Maastricht University Medical Centre, Maastricht, The Netherlands.
authors: Adriaan P
authors: AP
authors: de Bruïne
authors: The Netherlands Cancer Registry, Comprehensive Cancer Centre the Netherlands, Eindhoven, The Netherlands; Department of Public Health, Erasmus MC University Medical Centre, Rotterdam, The Netherlands.
authors: Valery E P P
authors: VE
authors: Lemmens
mesh_terms: D005260:Female; D006801:Humans; D008297:Male; D010190:Pancreatic Neoplasms / Q000473:pathology*; D011379:Prognosis; D015996:Survival Rate
keywords: Cytology; Histology; Pancreatic cancer; Pathological verification; Population-based; Survival; Treatment